BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25996489)

  • 1. Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.
    Kunze A; Poller B; Huwyler J; Camenisch G
    Drug Metab Pers Ther; 2015 Sep; 30(3):175-88. PubMed ID: 25996489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.
    Chu X; Shih SJ; Shaw R; Hentze H; Chan GH; Owens K; Wang S; Cai X; Newton D; Castro-Perez J; Salituro G; Palamanda J; Fernandis A; Ng CK; Liaw A; Savage MJ; Evers R
    Drug Metab Dispos; 2015 Jun; 43(6):851-63. PubMed ID: 25813937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data.
    Riede J; Poller B; Umehara K; Huwyler J; Camenisch G
    Eur J Pharm Sci; 2016 Apr; 86():96-102. PubMed ID: 26948853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans.
    Watanabe T; Kusuhara H; Maeda K; Kanamaru H; Saito Y; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2010 Feb; 38(2):215-22. PubMed ID: 19875501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins.
    Stevens LJ; Zhu AZX; Chothe PP; Chowdhury SK; Donkers JM; Vaes WHJ; Knibbe CAJ; Alwayn IPJ; van de Steeg E
    Drug Metab Dispos; 2021 Sep; 49(9):780-789. PubMed ID: 34330719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
    Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
    J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors.
    Fujino H; Saito T; Tsunenari Y; Kojima J; Sakaeda T
    Xenobiotica; 2004; 34(11-12):961-71. PubMed ID: 15801541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins.
    Filppula AM; Hirvensalo P; Parviainen H; Ivaska VE; Lönnberg KI; Deng F; Viinamäki J; Kurkela M; Neuvonen M; Niemi M
    Drug Metab Dispos; 2021 Aug; 49(8):658-667. PubMed ID: 34045219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions.
    Camenisch G; Umehara K
    Biopharm Drug Dispos; 2012 May; 33(4):179-94. PubMed ID: 22407504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.
    Barton HA; Lai Y; Goosen TC; Jones HM; El-Kattan AF; Gosset JR; Lin J; Varma MV
    Expert Opin Drug Metab Toxicol; 2013 Apr; 9(4):459-72. PubMed ID: 23331046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
    Schachter M
    Fundam Clin Pharmacol; 2005 Feb; 19(1):117-25. PubMed ID: 15660968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.
    Badolo L; Bundgaard C; Garmer M; Jensen B
    Eur J Pharm Sci; 2013 Jul; 49(4):767-72. PubMed ID: 23648783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
    Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
    Neuvonen PJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats.
    Lin CH; Hsu KW; Chen CH; Uang YS; Lin CJ
    Biochem Pharmacol; 2017 Oct; 142():216-228. PubMed ID: 28636885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights.
    Poulin P; Haddad S
    J Pharm Sci; 2018 Jul; 107(7):1791-1797. PubMed ID: 29567347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.
    Mao J; Tay S; Khojasteh CS; Chen Y; Hop CE; Kenny JR
    Pharm Res; 2016 May; 33(5):1204-19. PubMed ID: 26869174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation.
    Tornio A; Filppula AM; Niemi M; Backman JT
    Clin Pharmacol Ther; 2019 Jun; 105(6):1345-1361. PubMed ID: 30916389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?
    Corsini A; Ceska R
    Curr Med Res Opin; 2011 Aug; 27(8):1551-62. PubMed ID: 21682551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.